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Abstract
The evolutionary processes that drive universal therapeutic resistance in adult patients with diffuse 
glioma remain unclear1,2. Here, we analyzed temporally separated DNA sequencing data and 
matched clinical annotation from 222 patients with glioma. Through mutational and copy number 
analyses across the three major subtypes of diffuse glioma, we observed that driver genes detected 
at initial disease were retained at recurrence, while there was little evidence of recurrence-specific 
gene alterations. Treatment with alkylating-agents resulted in a hypermutator phenotype at 
different rates across glioma subtypes, and hypermutation was not associated with differences in 
survival. Acquired aneuploidy was frequently detected in recurrent gliomas characterized by 
presence of an IDH mutation but without 1p/19q codeletion and further converged with acquired 
cell cycle alterations and poor outcomes. We show that the clonal architecture of each tumor 
remains similar over time and that absence of clonal selection was associated with increased 
survival. Finally, we did not observe differences in immunoediting levels between initial and 
recurrent glioma. Our results collectively argue that the strongest selective pressures occur early 
during glioma development and that current therapies shape this evolution in a largely stochastic 
manner.
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INTRODUCTION
Diffuse glioma is the most common malignant brain tumor in adults and invariably relapse 
despite treatment with surgery, radiotherapy, and chemotherapy. The molecular landscape of 
glioma at diagnosis has been extensively characterized 3-9. While these efforts have led to 
the identification of driver genes and clinically relevant subtypes10,11, it is unknown how the 
glioma genetic landscape evolves over time and in response to therapy.
Intratumoral heterogeneity is a well-recognized characteristic of gliomas and results from 
selective pressures such as a limited availability of nutrients, clonal competition, and 
treatment12-15. Tumors are thought to circumvent these growth bottlenecks via dynamic 
competition of subclones resulting in the most favorable environment for tumor sustenance1. 
Recent studies have suggested that stochastic changes in clone frequency (i.e. neutral 
evolution) and immunogenic surveillance may further contribute to the observed 
intratumoral heterogeneity1617. An understanding of evolutionary dynamics at multiple time 
points is needed to develop strategies aimed at delaying or preventing the onset of tumor 
progression.
To investigate clonal dynamics over time and in response to therapeutic pressures, we 
established the Glioma Longitudinal Analysis (GLASS) Consortium. GLASS is a 
community-driven effort that seeks to overcome the logistical challenges in constructing 
adequately powered longitudinal genomic glioma datasets by pooling datasets from patients 
treated at institutions worldwide 18. We have analyzed longitudinal profiles across the three 
molecular glioma subtypes to identify the molecular processes active at initial and recurrent 
time points. These analyses identified few common features of glioma evolution across 
subtypes, and instead pointed toward highly variable and patient-specific trajectories of 
genomic alterations.
RESULTS
GLASS cohort
We pooled existing and newly generated longitudinal DNA sequencing datasets from 288 
patients treated at 35 hospitals (Supplementary Table 1, Extended Data Fig. 1). After 
applying quality filters, tumor samples from 222 patients with high-quality data in at least 
two time points were classified according to molecular markers into three major glioma 
subtypes: 1. IDH-mutant and chromosome 1p/19q co-deleted (IDHmutant-codel; n = 25) 2. 
IDH-mutant without chromosome 1p/19q codeletion (IDHmutant-noncodel; n = 63) and 3. 
IDH wild type (IDHwt; n = 134), in alignment with the World Health Organization 
classification of Central Nervous System tumors 10,11. For each patient we selected two 
time-separated tumor samples, henceforth initial and recurrence, for further analysis.
Mutational burdens and processes over time
We first evaluated temporal changes in mutational burden and processes to understand 
general patterns of glioma evolution. Mutation burdens in initial tumors were comparable 
with previously reported rates 6,7,19. 2.20 mutations (single-nucleotide variants and small 
insertions/deletions) per Megabase (Mutations/Mb) for IDHmutant-codels; 2.52 
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Mutations/Mb for IDHmutant-noncodels; and 2.85 Mutations/Mb for IDHwt glioma (Fig. 
1a; Extended Data Fig. 2a). Excluding DNA hypermutation cases (> 10 Mutations/Mb, n = 
35), the mutation burden increased after recurrence in 70% of the cohort (Extended Data 
Fig. 2a). To study changes during tumor progression, we separated mutations into three 
fractions: initial only, recurrence only, or shared. Interestingly, private fraction but not shared 
fraction mutation burdens were comparable between subtypes (Extended Data Fig. 2b). 
Patient age at diagnosis was significantly associated with the shared mutational burden and 
to a lesser extent the mutation burden private to the initial tumor (Extended Data Fig. 2c). 
On average, tumors with longer time to recurrence had slightly higher mutation burdens 
(Extended Data Fig. 2d).
These fraction-specific differences in mutation burden suggested that the activity of distinct 
mutational processes may also be time-dependent. We therefore classified mutations in each 
fraction according to the Catalogue of Somatic Mutations in Cancer (COSMIC) signature 
database20. As expected, signature activity was closely related to subtype and fraction (Fig. 
1b, Extended Data Fig. 3a). Signature 1 (aging) was nearly always the dominant signature 
amongst shared mutations in IDHwt tumors, whereas the shared fraction in IDHmut-
noncodel and IDHmut-codel tumors - tumor subtypes associated with a younger age of 
diagnosis - additionally showed a strong presence of signature 16 (unknown etiology). 
Signatures 3 (double strand break repair) and 15 (mismatch repair) along with signature 8 
(unknown etiology) were mostly confined to the private fractions, suggesting that these 
processes were of lesser importance to tumor maintenance than those associated with aging.
Treatment of glioma includes alkylating agents that can induce post-treatment 
hypermutation21-23. We observed enrichment of the associated signature 11 in recurrent 
tumors with a mutational load exceeding 10 Mutations/Mb and treated with alkylating 
agents (Fig. 1a, Extended Data Fig. 3b). Treatment-associated hypermutation occurred most 
frequently among IDHmutant-noncodels (47%), followed by IDHmutant-codels (25%), and 
IDHwt gliomas (16%) (Fig. 1c). The difference in the proportion of hypermutation events 
was significantly different between the three glioma subtypes (Fisher’s exact-test P = 
2.0e-03), suggesting that IDHmutant noncodels are most sensitive to developing a 
hypermutator phenotype 24.
Treatment-induced hypermutation has been associated with disease progression23. We did 
not find overall survival differences between alkylating agent-treated hypermutators and 
alkylating agent-treated non-hypermutators independent of age, subtype, and MGMT 
methylation status (Fig. 1d, Supplementary Table 2a-b). In order to further assess the 
pathogenicity of acquired mutations, we studied their clonality25. Newly acquired clonal 
mutations have penetrated most of the tumor (i.e., a selective sweep) between initial and 
recurrence and mark clonal expansion 26. Conversely, acquired subclonal mutations are less 
prevalent, and therefore less likely to drive disease progression. Previous reports have 
suggested that alkylating agent-associated mutations hypermutation are frequently clonal27. 
We found that in 48% of hypermutated tumors a majority of the recurrence-only mutations 
were clonal, potentially reflecting cases where a selective sweep occurred (Extended Data 
Fig. 4a). However, IDHmut-noncodel hypermutators with predominantly clonal mutations 
did not show differences in survival compared with those harboring predominantly subclonal 
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mutations (log-rank test P = 0.38, Extended Data Fig. 4b). Alkylating agents such as 
temozolomide prolong survival of adult patients with glioma28,29. Our results show that 
treatment-induced hypermutation is common across subtypes and does not associate with a 
reduced overall survival supporting the noted benefit of alkylating agent therapy.
Selective pressures during glioma evolution
Environmental and treatment-induced pressures may drive changes in clonal architecture at 
recurrence. To evaluate selection over time we clustered copy number changes and 
mutations based on their cancer cell fraction (CCF). CCF values represent the fraction of 
cancer cells harboring a given alteration and reflect the relative timing of events, since 
alterations that are present in a subset of cancer cells likely occurred later than events present 
in all cancer cells (Fig. 2a). Most tumors (84%) demonstrated a mutational cluster with CCF 
> 50% that persisted from the initial tumor into recurrence, likely reflecting the tumor trunk 
and harboring the tumor-initiating driver mutations (Fig. 2b, Extended Data Fig. 5a)30. To 
determine changes in clonal dominance over time we ranked clusters within each sample by 
their CCF and found similarities in clonal architecture throughout the course of disease 
(Kendall rank correlation, tau = 0.20, P = 3.76E-24, Fig. 2b, Extended Data Fig. 5b-d). 
These results suggested that the clonal structure at initial disease mostly persisted into 
recurrence.
To deepen our assessment of selective pressures, we evaluated selection in initial and 
recurrent tumors by determining the normalized ratio between non-synonymous and 
synonymous mutations (dNdScv). Higher ratios (> 1) suggest positive selection, and ratios 
less than one suggest negative selection . We found evidence for positive selection at both 
time points despite differences between subtypes (Fig. 2c). Separating mutations into 
mutational fractions demonstrated that shared but not private mutations showed positive 
dN/dS ratios in all three glioma subtypes indicating that only shared mutations (including 
truncal mutations) are likely subject to positive selection (Fig. 2c). The dN/dS ratio of 
initial-only mutations showed that these are neither positively nor negatively selected for, 
while recurrence-only mutations were subject to negative selection in IDHwt.
To verify the reduced selective pressure in the private mutations we used an orthogonal 
method to test for evidence of selection (neutralitytestr)31. The method uses variant allele 
frequency distributions and estimated mutation rates to detect whether profiles significantly 
deviate from a model of neutral evolution (i.e. as depicted by a linear relationship in Fig. 
2d). In accordance with dNdScv results, private mutations demonstrated dynamics consistent 
with neutral evolution (Fig. 2d). Shared subclonal mutations deviated from linearity and 
were consistent with selection both in non-hypermutators and hypermutators (Fig. 2d, 
Extended Data Fig. 6a-b), providing additional evidence that the strongest selective forces 
occur early in gliomagenesis.
Cohort-level analysis of selection masks the heterogeneity that exists in individual 
evolutionary trajectories. To determine the selective effects at each tumor time point we used 
a Bayesian framework (SubClonalSelection) which simultaneously provides sample-specific 
probabilities for both selection and neutrality while modeling sources of noise in sequencing 
data. The classification of a sample as “selection” or “neutral” is determined by whichever 
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model has the greater probability. Classification as “neutral” reflects the accumulation of 
random mutations that are not subject to selection. Given the stringent algorithm 
requirements, 183 patients were included in this analysis with at least one time point, and 
104 patients with both time points (16 IDHmutant-codels, 29 IDHmutant-noncodels, 59 
IDHwt, Supplementary Table 3). Neutral to neutral was the most common evolutionary 
trajectory across all three subtypes (52%), and IDHwt tumors displayed the highest observed 
selection at any time point with selection detected in 64% of tumors (Fisher’s exact test P = 
0.01, Fig. 2e, Supplementary Table 3). IDHwt gliomas with evidence for selection at 
recurrence had a shorter overall survival than IDHwt gliomas classified as neutral at 
recurrence (P = 2.7E-02; log-rank statistic, Fig. 2f), suggesting that subclonal competition 
associates with more aggressive tumor behavior. To address the limitations of smaller 
sample sizes in the IDH-mutant subtypes, we performed a Cox proportional hazards model 
including age at first diagnosis, all three glioma subtypes, and mode of selection at 
recurrence. This analysis revealed that selection at recurrence was significantly associated 
with shorter survival across subtypes (HR = 1.53 95% CI 1.00–2.41, P = 4.8E-02, 
Supplementary Table 4). We next investigated whether radiation and chemotherapy imposed 
a selective effect, by comparing the evolutionary status at recurrence with treatment and 
other clinical variables. We did not observe significant associations between subclonal 
selection and radiation therapy or chemotherapy (Fisher’s exact-test P > 0.05, 
Supplementary Table 5), suggesting that standard therapeutic approaches for glioma have 
limited impact on the subclonal tumor architecture. While high-depth sequencing datasets 
may be required to detect subtle selective effects26, our analyses raise the possibility that the 
survival benefit derived from standard chemoradiation results from tumor cell elimination 
where treatment sensitivity of individual cells is not determined by genetic factors.
Driver alteration frequencies across time
We evaluated how stability, acquisition, and loss of mutation and copy number drivers6 over 
time impact glioma evolution. We used dNdScv to nominate 12 candidate mutation driver 
genes at both time points (Q < 0.05, Fig. 3a, Extended Data Fig. 7a) and determined 
significant copy number alterations that recapitulated previously identified drivers (Extended 
Data Fig. 7b). Mutations in IDH1 and co-occurring 1p/19q chromosome-arm loss have been 
suggested as glioma-initiating events1, which was corroborated by the observation that these 
events were never lost or acquired during the surgical interval (Fig. 3a, Extended Data Fig. 
8a). Similarly, we observed that TERT promoter mutations were almost always shared in the 
IDHmutant-codel and IDHwt, though many samples lacked sufficient coverage in this GC-
rich region. Chromosome 7 gains and chromosome 10 losses were present in a large 
majority of IDHwt initial tumors and persisted into recurrence.
Shifts in the fraction of cancer cells harboring an event may also indicate a time dependency 
of drivers. We determined changes in cellular prevalence of shared driver events by ordering 
events in each sample by their CCF (Extended Data Fig. 9). ATRX mutations in IDHmutant-
noncodel initial tumors demonstrated lower CCFs than TP53 (P = 0.03) and IDH1 (P = 0.10) 
mutations, suggesting IDH1 and TP53 mutations precede ATRX inactivation1. There was no 
difference in CCF between IDH1 and TP53 amongst initial gliomas (P = 0.98), however, 
IDH1 mutations demonstrated significantly lower CCFs compared with TP53 (P = 0.0018) 
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in recurrent gliomas. We did not observe any CCF differences among driver mutations 
detected in IDHwt tumors at either time point. Chromosome 10 deletion CCFs were higher 
compared to chromosome 7 amplifications (P = 0.0036) implying that chromosome 10 
deletions arise earlier 32. Similarly, there was no difference in CCF between CDKN2A 
deletion and EGFR amplification (P = 0.70). EGFR and chromosomal arm events 
significantly differed (i.e. 10p del vs EGFR amp, P = 0.0019) but not CDKN2A deletion and 
chromosomal events (i.e. 10p del vs CDKN2A del, P = 0.33). The consistently high CCF for 
EGFR amplifications could indicate that these events precede even some larger 
chromosomal aberrations, while not excluding the possibility that high levels of 
extrachromosomal EGFR 33 artificially inflate CCF.
Longitudinal changes in CCF values provide additional insights into evolutionary dynamics. 
For instance, the CCF value may increase when a driver event is linked to clonal expansion, 
or conversely, decrease when a clone is outcompeted. Most individual drivers did not 
demonstrate significant consistent CCF changes between the initial tumor and recurrence 
(Extended Data Fig. 10a). A notable exception was the TP53 mutation CCF that increased 
over time (P = 0.037) in IDHmut-noncodels, but not IDHwt gliomas (P = 0.13, Extended 
Data Fig. 10b). We did not observe any differences in IDH1 CCF over time among IDHmut-
noncodel tumors, possibly because the general trend of these tumors to increase in CCF is 
counteracted by the biological loss of relevance of mutant IDH1 over time (Extended Data 
Fig. 10c). Indeed, a gross comparison of all shared mutation CCFs revealed an increase in 
recurrent IDHmut-noncodel tumors (P < 0.0001), which may reflect increased clonality and 
a reduction in intratumoral heterogeneity (Extended Data Fig. 10d). In contrast, shared CCFs 
decreased in IDHwt tumors, potentially indicating a general increase in intratumoral 
heterogeneity at recurrence (P < 0.0001, Extended Data Fig. 10d). We confirmed that 
IDHmutant-noncodel CCF increases and IDHwt decreases were not biased by patients with 
high mutation burden through the classification of patient-specific shared mutation CCF 
change (Extended Data Fig. 10e).
We next investigated whether specific somatic alterations were acquired or lost over time. 
Gene-specific enrichment of many recurrence-only mutations was found in hypermutated 
tumors, but there was no enrichment for somatic gene alterations in non-hypermutators 
suggesting that glioma recurrence is not directed by particular sets of mutations (Extended 
Data Fig. 8b). Within subtypes we detected an enrichment in CDKN2A homozygous 
deletions (Fig. 3a, Extended Data Fig. 8a) in recurrent IDHmutant-noncodels, which was 
corroborated by additional cell cycle gene alterations (focal gain of CCND2, CDK4, CDK6, 
and mutation or homozygous loss of RB1). Mutations in cell cycle checkpoint control genes 
are associated with genomic instability 34. Therefore, we analyzed aneuploidy levels by 
determining the proportion of the genome that had undergone aneuploidy events (Extended 
Data Fig. 11a-b). We observed that IDHmutant-noncodel tumors had a higher level of 
aneuploidy at recurrence (Wilcoxon rank sum test P = 1.4E-06 total aneuploidy, p = 8.6E-03 
arm-level aneuploidy, Extended Data Fig. 11c-d) with tumors carrying acquired cell cycle 
gene alterations displaying the largest increases in aneuploidy (P = 7.6E-06; Wilcoxon rank 
sum test, Fig. 3b). We reasoned that CDKN2A deletions may precede aneuploidy. 
Homozygous CDKN2A deletions had significantly higher CCFs compared to average CNV 
CCF across the genome (as a surrogate for aneuploidy related copy number changes), 
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suggesting that CDKN2A loss occurred prior to aneuploidy (Fig. 3c). These alterations may 
hasten disease progression as patients with either cell cycle alterations or the largest 
increases in aneuploidy at recurrence demonstrated significantly shorter survival than 
patients without these alterations (log-rank test P < 0.0001, Fig. 3d). Taken together, the 
persistence of drivers over time and the paucity of consistent change imply that therapy does 
not result in selection of specific sets of molecular changes.
Immunoediting activity in glioma
We next investigated how the immune microenvironment affects evolutionary trajectories. 
The immune system may prune tumor cells carrying immunogenic (neo-)antigens, resulting 
in the selection of subclones capable of evading the immune response. Evidence of this 
immunoediting process has been shown in several cancer types, including glioma 35-38, and 
suggests active immunosurveillance that may be therapeutically exploited 39. We 
computationally predicted neoantigen-causing mutations40. As expected, the neoantigen 
load across the GLASS cohort was strongly correlated with exonic mutation burden 
(Spearman’s Rho = 0.89), with 42% of nonsynonymous exonic mutations giving rise to 
neoantigens on average. This fraction did not significantly differ by glioma subtype or 
between initial and recurrent tumors (P > 0.05, Wilcoxon rank-sum test; Fig. 4a). The most 
common neoantigen arose from the clonal R132H mutation in IDH1 and was present in of 
22 out of 88 IDH-mutant initial and recurrent tumors. Beyond mutations in IDH1, no 
mutations gave rise to a neoantigen found in more than three tumors at a given timepoint 
(Supplementary Table 6). Across the dataset, neoantigens and non-immunogenic mutations 
exhibited similar changes in cancer cell fractions between initial and recurrent tumors 
indicating a lack of neoantigen-specific selection processes over time (Extended Data Fig. 
12a).
We then examined the extent to which immunoediting occurred by comparing each sample’s 
observed neoantigen rate to an expected rate that was empirically derived from our dataset. 
The output of this approach is a normally distributed set of ratios centered at 1. Samples 
with an observed-to-expected neoantigen ratio < 1 exhibit evidence of neoantigen depletion 
relative to the rest of the dataset, and thus are more likely to have been immunoedited. We 
found that none of the three glioma subtypes harbored observed-to-expected ratios that 
significantly differed from 1 (P > 0.05, one sample t-test), though IDHwt tumors exhibited 
significantly lower scores compared to IDHmut-noncodels (t-test, P = 0.04; Fig. 4b). We 
additionally did not observe an association between the observed-to-expected ratio and 
survival when adjusting for subtype and age (Wald test, P > 0.05), nor was there a difference 
between samples with neutral evolution dynamics compared to those exhibiting evidence of 
subclonal selection. When comparing samples longitudinally, we found that the observed-to-
expected neoantigen ratio was strongly correlated between initial and recurrent tumors of 
each patient (Pearson’s R = 0.73, P = 5E-38), suggesting that the neoantigen depletion level 
in the recurrence reflects that of the initial tumor (Fig. 4c).
Immunoediting is most likely to take place in the tumors with high cytolytic activity and low 
levels of immunosuppressive activity38. Hypermutators, which have high neoantigen loads, 
have previously been associated with highly cytolytic microenvironments 37. However, we 
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did not observe any differences in the observed-to-expected neoantigen ratio between 
hypermutated recurrent tumors and their initial counterparts, nor did we observe differences 
between hypermutated and non-hypermutated recurrent tumors, indicating that 
immunoediting activity is not related to the total number of mutations in a sample (Wilcoxon 
rank-sum test P > 0.05; Extended Data Fig. 12b). To more directly determine whether there 
were immunologic factors associated with neoantigen depletion, we analyzed CIBERSORT 
immune cell fractions from a subset of samples that had undergone expression profiling in a 
previous study (n = 84 from 42 tumor pairs) 37,41. Initial tumors with an observed-to-
expected neoantigen ratio >1 exhibited significantly higher levels of CD4+ T cells than those 
with a ratio < 1, while recurrent tumors with a ratio > 1 exhibited significantly higher levels 
of macrophages, neutrophils, and significantly lower levels of plasma cells relative to those 
with ratio < 1 (P < 0.05, Wilcoxon rank-sum test; Extended Data Fig. 12c).
While we did not detect many factors associated with the observed-to-expected neoantigen 
ratio, we did observe that the ratio was significantly associated with the total number of 
unique HLA loci in a patient (Spearman’s Rho = 0.28, P = 2E-9), reflecting similar findings 
in lung cancer42. This may bias analyses comparing the ratio across patients. To determine 
whether immunoediting varies over time in a patient-agnostic manner, we compared the 
observed-to-expected neoantigen ratio derived from a sample’s clonal mutations, which 
likely arose earlier in tumor evolution, to that derived from their subclonal mutations, which 
likely arose later. We did not observe a significant difference in the observed-to-expected 
neoantigen ratio of each patient’s clonal and subclonal neoantigens, regardless of glioma 
subtype or whether the sample was an initial tumor or recurrence (P > 0.05, paired t-test; 
Fig. 4d). Together, these analyses suggest that neoantigens in glioma are not exposed to 
differing levels of selective pressure throughout their development.
DISCUSSION
We reconstructed the evolutionary trajectories of 222 patients with glioma to better 
understand treatment failures and tumor progression. The longitudinal molecular profiles 
revealed common features such as acquired hypermutation and aneuploidy, but highlighted 
the individualistic paths of post-treatment glioma evolution. Our results provide evidence 
that current standard of care therapies do not frequently coerce glioma down predictable 
paths. Instead, an unexpected number of gliomas appeared to stochastically evolve following 
early driver events. We expect that continuing to profile patient tumors over time using 
comprehensive sequencing approaches will identify additional common evolutionary paths. 
Our results here highlight the exciting prospects of several ongoing efforts that may inform 
new glioma therapies.
The observation that treatment-induced hypermutation occurred across subtypes, but did not 
confer a detrimental effect on patient survival leaves the clinical significance of glioma 
hypermutation uncertain21-24,27. Future analyses that consider the number of therapy cycles 
and MGMT DNA methylation status will help to elucidate factors that predispose tumors to 
hypermutation and identify therapies that effectively exploit this phenotype’s vulnerabilities 
(e.g., high mutation burden). Acquired cell cycle alterations and aneuploidy in recurrent 
IDHmut-noncodel gliomas also provide a rationale to target these more aggressive 
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phenotypes with CDK inhibitors43 or with compounds that disrupt microtubule dynamics44. 
Finally, our analyses revealed that immunoediting activity does not vary in glioma over time, 
though we did observe variation between individual patients. Additional molecular and 
immunological data are needed to fully understand the impact this variability has on glioma 
evolution and to devise therapies directed at a glioma’s immunogenicity17. To this end, we 
found that clonal neoantigens arising from the IDH1 R132H mutation persisted from the 
initial tumor into the recurrence, justifying neoantigen vaccine approaches as treatments for 
initial and recurrent glioma45,46.
Collectively, these findings help shape our perspective on what constitutes an optimal 
treatment, and what approaches would result in the greatest removal or killing of glioma 
cells possible. Genomic characterization efforts such as TCGA have greatly increased our 
understanding of glioma biology, but were limited to a single snapshot in evolutionary time. 
The GLASS resource provides a framework to study the patterns of glioma evolution and 
treatment response.
Methods
Data reporting
No statistical methods were used to predetermine sample size.
DNA sequencing and data collection
The GLASS dataset consists of both unpublished and published sequencing data as outlined 
in Supplementary Table 1. Among the cohort were exomes from 436 glioma samples (200 
patients), whole-genome from 165 glioma samples (78 patients), with overlapping exome/
whole-genome data on 78 glioma samples (38 patients). A matching germline sequence was 
available for all patients. The dataset includes 257 sets of at least two time-separated tumor 
samples, seventeen standalone recurrences, and 19 patients with at least two geographically 
distinct tumor portions. More specifically, the dataset includes exome or whole-genome 
sequencing data on 211 primary gliomas, 234 first recurrences, 32 second recurrences, 11 
third recurrences and one fourth recurrence (Supplementary Table 7).
Newly generated whole genome sequencing data for the Chinese University of Hong Kong 
(HK), Northern Sydney Cancer Centre (NS) and MD Anderson Cancer Center (MD) cohorts 
were subjected to 150 base paired-end sequencing. The HK samples were sequenced using a 
HiSeqX while the NS and MD cohorts were sequenced using a NovaSeq according to 
Illumina’s protocols. Whole exome capture was performed using the following platforms as 
reported in previous publications. Agilent SureSelect Human All Exon 50Mb capture kit 
was used for patients SF-0001- SF-0021, Agilent SureSelect Human All Exon V4 capture 
kit was used for patients SF-0024 – SF-0029 in the UC San Francisco cohort. Agilent 
SureSelect Human All Exon v4 or v5 was used to capture samples in the Kyoto University 
cohort. Samsung Medical Center cohort reported using Agilent SureSelect kit for patients 
SM-R056 – SM-R071, SM-R075, SM-R076, SM-R095- SM-R114 while Illumina TruSeq 
Exome-capture kit was used for patient SM-R072. Exome capture was performed using 
Agilent SureSelect Human All Exon 50 Mb in The Cancer Genome Atlas (TCGA)-GBM 
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cohort and Agilent SureSelect Human All Exon v2.0, 44Mb kit in the TCGA-LGG cohort. 
Columbia University cases were captured using Agilent V3 50M kit, sequencing 90bp PE 
for samples R009-TP, R009R1, R011TP, R011R1, R014TP, R014R1, R017-R1, R018-R1, 
R019-R1. Mapping files of initial tumor and normal samples of patients R017 – R019 were 
obtained from TCGA through CG-hub. All other samples were captured using Agilent 
SureSelect XT Human All Exon v4 Kit, PE, 80M reads, 150X on target coverage. Samples 
in the Henry Ford Hospital cohort were multiplexed and sequenced using Illumina HiSeq 
2000 by the Sequencing and Microarray Facility at an average target exome coverage of 
100× using 76-bp paired-end reads. Samples in the HK cohort were subjected to 75 base 
paired-end sequencing for HK-0001 – HK-0004 as performed NextSeq in high output mode. 
In the Leeds Cohort (LU) SureSelectXT V5 kit (PE100) was used to construct exome 
libraries. Illumina TruSeq Exome capture kit was used for samples at the Medical University 
of Vienna – CeMM.
GLASS identifiers
A GLASS barcode system was created, based on TCGA barcode design, in an effort to de-
identify patient information and provide an organized framework for the different pieces of 
the dataset.
GLASS barcodes are composed of 24 characters. The first four characters specify the project 
(either GLSS or TCGA). All datasets submitted to the GLASS consortium, published and 
unpublished, were given the GLSS project ID. Samples that were part of the TCGA cohorts 
(TCGA GBM and TCGA LGG) were given a TCGA designation. The next two characters 
designate the center where the samples were either acquired or sequenced (Supplementary 
Table 7). This is followed by the four-character center specific patient identification that was 
kept as close as possible to the patient identification provided by the collaborators to allow a 
simplified trace back process. Patient data is divided by a relative sample type, such as initial 
tumor (TP), recurrent tumor (R1), normal tissue (NB, NM, etc), or metastatic tumor sample 
(M1). If there was more than one recurrence the relative number was specified following 
“R”. Some patients had surgeries for which a biospecimen was unavailable. Thus, a surgical 
number was also provided to indicate temporal ordering (Supplementary Table 8). To 
include spatially separated samples the portion designation was added, which is followed by 
one character specifying the type of analyte, either DNA (D) or RNA (R). As there is 
variation in the sequencing analysis, a three-character designation represents either whole 
genome (WGS) or whole exome sequencing (WXS). The last part of the GLASS barcode is 
a six-character designation unique to each barcode that was randomly generated.
Computational pipelines
All pipelines were developed using snakemake 5.2.2 47. Unless otherwise stated, all tools 
mentioned are part of the GATK 4 suite 48. All data was collected at a central location (The 
Jackson Laboratory) and was analyzed using homogenous pipelines capable of processing 
both raw fastq files as well as re-process previously analyzed bam files.
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Alignment and pre-processing
Data pre-processing was conducted in accordance to the GATK Best Practices using GATK 
4.0.10.1. Briefly, aligned BAM files were separated by read group, sanitized and stripped of 
alignments and attributes using ‘RevertSam’, giving one unaligned BAM (uBAM) file per 
readgroup. Uniform readgroups were assigned to uBAM files using 
‘AddOrReplaceReadgroups’. Similarly, unaligned fastq files were assigned uniformly 
designated readgroup attributes and converted to uBAM format using ‘FastqToSam’. uBAM 
files underwent quality control using ‘FastQC 0.11.7’. Sequencing adapters were marked 
using ‘MarkIlluminaAdapters’. uBAM files were finally reverted to interleaved fastq format 
using ‘SamToFastq’, aligned to the b37 genome (‘human_g1k_v37_decoy’) using ‘BWA 
MEM 0.7.17’, attributes were restored using ‘MergeBamAlignment’. ‘MarkDuplicates’ was 
then used to merge aligned BAM files from multiple readgroups and to mark PCR and 
optical duplicates across identical sequencing libraries. Lastly, base recalibration was 
performed using ‘BaseRecalibrator’ followed by ‘ApplyBQSR’. Coverage statistics were 
gathered using ‘CollectWgsMetrics’. Alignment QC was performed running 
‘ValidateSamFile’ on the final BAM file and QC results were inspected using ‘MultiQC 
1.6a0’ 49. A haplotype database for fingerprinting was generated using a modified version of 
the code on https://github.com/naumanjaved/fingerprint_maps. The tool 
‘CrosscheckFingerprints’ was used to confirm that all readgroups within a sample belong to 
the same individual, and that all samples from one individual match. Any mismatches were 
marked and excluded from further analysis.
Variant detection
Variant detection was performed in accordance to the GATK Best practices using GATK 
4.1.0.0. Germline variants were called from control samples using Mutect2 in artifact 
detection mode and pooled into a cohort-wide panel of normals. Somatic variants were 
subsequently called in individual tumor samples (single-sample mode) and in entire patients 
using GATK 4.1 Mutect2 in multi-sample mode. Mutect2 was given matched control 
samples, the aforementioned panel of normals and the gnomAD germline resource as 
additional controls. Cross-sample contamination was evaluated using ‘GetPileupSummaries’ 
and ‘CalculateContamination’ run for both tumor and matching control samples. Read 
orientation artifacts were evaluated using ‘CollectF1R2Counts’ and 
‘LearnReadOrientationModel’. Somatic likelihood, read orientation, sequence context, 
germline and contamination filters were applied using ‘FilterMutectCalls’.
Variant post-processing
BCFTools 1.9 was used to normalize, sort and index variants50. A consensus VCF was 
generated from all variants in the cohort, removing any duplicate variants. The consensus 
VCF file was annotated using GATK 4.1 Funcotator and the v1.6.20190124s annotation data 
source. Allele frequencies (AFs) from multi-sample Mutect2 were used to compare AFs 
between related samples. Multi-sample Mutect2 calls and filters mutations across a patient 
as a whole and does not determine mutation calls in a single samples. Single-sample 
mutation calls were overlaid on the multi-sample calls to infer whether variants were called 
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in individual samples. Single-sample called variants that were not present in the multi-
sample callset were discarded.
Mutational burden
Mutational burden was calculated as the number of mutations per megabase (Mb) 
sequenced. A minimum coverage threshold of 15x was required for each base. DNA 
hypermutation was defined for recurrent tumors with greater than 10 mutations per Mb 
sequenced as these values were considered outliers (1.5 times the interquartile range above 
the upper quartile). Notably, there were a few initial gliomas that demonstrated a mutational 
frequency above 10 mutations per Mb. However, the “hypermutation” classification was 
restricted to only patients with this level at recurrence since these likely reflect different 
evolutionary paths.
Mutational signatures
The relative contributions of the COSMIC mutational signatures were determined from a 
patient’s initial-only, recurrence-only, and shared mutations by solving the non-negative-
least squares (NNLS) problem for each set of mutations using the 30 signatures from version 
2 (March 2015). Six signatures were dominantly enriched in at least 3% of the fractions and 
we resolved the NNLS using the reduced six-signature model to increase accuracy and 
reduce noise.
Copy number segmentation
Copy number identification was performed according to the GATK Best Practices and is 
outlined briefly here. The pipeline differs slightly for whole genomes and whole exomes. 
For genomes, the genome was segmented into 10kb bins using ‘PreprocessIntervals’. For 
exomes, overlapping regions between several commonly used capture kits (Broad Human 
Exome b37, Nextera Rapid Capture, TruSeq Exome, SeqCap EZ Exome V3, Agilent 
SureSelect V4, Agilent SureSelect V7) were identified using ‘bedtools multiIntersectBed’. 
The tool ‘PreprocessIntervals’ was used to apply 1kb padding and to merge overlapping 
intervals. In parallel, ‘SelectVariants’ was used to subset the gnomAD resource of germline 
variants to variants with a population AF greater than 5%. Next, ‘CollectReadcounts’ was 
used to count reads in the bins generated by ‘PreprocessIntervals’ separately for autosomes 
and allosomes. In parallel, ‘CollectAllelicCounts’ was used to count reference and alternate 
reads at gnomAD variant sites with a population AF greater than 5%. The cohort was 
subsequently split into batches determined by sequencing center and 
‘CreateReadCountPanelOfNormals’ was used to create a panel of normal (PON) for each 
batch. PONs were created separately for allosomes and autosomes, and allosomes were 
separated further by sex. To further improve the panel of normals, GC content annotation of 
each interval as determined by ‘AnnotateIntervals’ were given. Next, ‘DenoiseReadCounts’ 
was used to denoise the binned readcounts output by ‘CollectReadCounts’, given a PON 
determined by batch, chromosomes (allosomes or autosomes) and sex. Denoised copy ratios 
were plotted and inspected for quality concerns using ‘PlotDenoisedCopyRatios’. The tool 
‘ModelSegments’ is an implementation of a gaussian-kernel binary-segmentation algorithm 
and was used to merge contiguous segments and assign copy and allelic ratios. The results of 
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this segmentation were plotted using ‘PlotModeledSegments’ and inspected for quality 
concerns.
Copy number calling
A copy number caller loosely based on GATK ‘CallCopyRatioSegments’ (which in turn is 
based off of ReCapSeg) and GISTIC was implemented to call both arm-level and high-level 
copy number changes, respectively51,52.
Segments (from ‘ModelSegments’) with a non-log2 copy ratio between 0.9 and 1.1 were 
determined to be neutral. These segments were then weighted by length and a weighted 
mean and standard deviation (sd) non-log2 copy ratio (once-filtered) were determined again. 
Outlier segments are removed and once again a weighted mean and sd non-log2 copy ratio 
(twice-filtered) were determined. Segments with a non-log2 copy ratio between 0.9 and 1.1 
and segments within two standard deviations of the twice-filtered mean were determined to 
be neutral, and segments outside of these boundaries were determined to have a low-level 
amplification or deletion, depending on the direction.
The weighted mean and sd of the non-log2 copy ratio (once-filtered) was then determined 
individually for each chromosome arm. Outlier segments were removed and the weighted 
mean and sd of the non-log2 copy ratio (twice-filtered) was determined again. In order to 
determine a high-level amplification and deletion threshold, the most highly amplified and 
deleted chromosome arms were selected, respectively. The twice-filtered mean plus (high 
level amplification) or minus (high level deletion) two times the sd of the selected arms were 
used as high-level thresholds.
Gene level copy number were called by intersecting the gene boundaries with the segment 
intervals and by calculating the weighted non-log2 copy ratio for that gene. The copy 
number call for that gene was then determined by comparing the gene-level non-log2 copy 
ratio to the previously determined thresholds.
dNdScv
The R package dNdScv53 (https://github.com/im3sanger/dndscv) was run using the default 
and recommended parameters for all mutations in initial tumor samples, recurrent tumor 
samples, and for each mutational fraction (unique to initial, unique to recurrent and shared). 
All analyses were conducted separately within the three main tumor subtypes.
Aneuploidy calculation
The most reductive metric of aneuploidy was computed by taking the size of all non-neutral 
segments divided by the size of all segments. The resulting aneuploidy value indicates the 
proportion of the segmented genome that is non-diploid.
In parallel, an arm-level aneuploidy score modeled after a previously described method was 
computed54. Briefly, adjacent segments with identical arm-level calls (−1, 0 or 1) were 
merged into a single segment with a single call. For each merged/reduced segment, the 
proportion of the chromosome arm it spans was calculated. Segments spanning greater than 
80% of the arm length resulted in a call of either −1 (loss), 0 (neutral) or +1 (gain) to the 
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entire arm, or NA if no contiguous segment spanned at least 80% of the arm’s length. For 
each sample the number of arms with a non-neutral event was finally counted. The resulting 
aneuploidy score is a positive integer with a minimum value of 0 (no chromosomal arm-
level events detected) and a maximum value of 39 (total number of autosomal chromosome 
arms excluding the short arms for chromosomes 13, 14, 15, 21, and 22).
Estimates of evolutionary pressures
Evolutionary pressures were evaluated both by variant status and glioma subtype using the 
neutralitytestr algorithm as previously described (R-package: neutralitytestr version: 0.0.2, 
https://github.com/marcjwilliams1/neutralitytestr)31. Individual variant allele frequency 
vectors were merged at the level of glioma subtype by variant status. Only mutations found 
in copy-neutral regions should were included in these analyses. For all else, default 
parameters were used. Merged VAF distributions were deemed to be selected when the 
neutral null hypothesis was rejected using several metrics. Tests for neutrality required that 
both R2 values < 0.98 and the area between the two curves of 1) merged VAF data and 2) a 
normalized distribution expected under neutrality to be significantly different.
The SubclonalSelection algorithm was applied to GLASS mutation data to measure the 
selection strength in individual tumor samples (Julia package: SubclonalSelection, https://
github.com/marcjwilliams1/SubClonalSelection.jl)16. Patients that had samples at both 
timepoints with a TITAN-defined purity estimate >= 0.5 and >= 25 subclonal mutations in 
non-diploid regions were included. Mean coverage across all mutations was used as the 
“read_depth” input parameter and the model was run with the recommended 106 iterations 
and 1000 particles. Samples were classified as neutral or selected based on the model that 
had the highest probability, in line with the prior applications to TCGA data16. Classification 
based on the highest model probability yielded stable results there was not a significant 
change in proportions when setting a higher classification probability threshold (P > 0.05, 
Pearson’s Chi-square test, for both probability thresholds of 0.6 and 0.7). At all three 
probability thresholds (0.5, 0.6, and 0.7), Kaplan-Meier survival analyses between selection 
at recurrence and overall survival continued to indicate that patients with IDHwt tumors that 
were selected had a worse overall survival (P = 0.03 (n=81), P = 0.01 (n=66), P = 0.01 
(n=56) respectively).
Mutation clonality
Each patient’s clonal architecture was inferred using PyClone (version 0.13.1) by grouping 
SNVs into clonal clusters (https://github.com/aroth85/pyclone)55. The patient-level input 
mutation matrix was reduced by limiting to sites with at least 30x coverage across all 
samples. PyClone was subsequently ran using a binomial density model, connected 
initiation, and 10000 iterations. Sample purities were provided for each patient and parental 
copy number (minor and major allele counts) from TITAN were given. PyClone results were 
post-processed using a burn-in of 1000, thin of 1, minimum cluster size of 2 and a maximum 
number of clusters per patient of 12. Individual mutations were determined to be clonal if 
the PyClone cancer cell fraction (CCF) values were >= 0.5, subclonal for mutations with 
CCF >= 0.1 and CCF <0.5, mutations were considered non-clonal when CCF < 0.1 as 
previously described 56.
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CNV clonality
Allele specific copy number, tumor purity and ploidy estimates were derived using a 
probabilistic model (TITAN, version 1.19.1) for both whole genome and whole exome 
sequencing samples 57. TITAN was supplied with the tumor denoised readcounts output by 
GATK DenoiseReadCounts and the tumor allelic counts at loci found to be heterozygous in 
control samples output by ModelSegments. An ‘alphaK’ (and ‘alphaKHigh’) parameter of 
2500 and 10000 was used for exomes and genomes, respectively. The patient sex was 
provided in order to improve fitting allosomes. For each tumor-control pair TITAN was ran 
assuming an initial ploidy of two or three, and assuming 1 to 3 clusters, resulting in a total of 
six possible solutions per tumor/control pair. To select the optimal solution, TITAN’s 
internal selectSolution function was used with a threshold of 0.15 giving additional weight 
to diploid solutions.
Timing analysis
The CCF values output by TITAN or PyClone were used for separately timing copy number 
changes or mutations. To time specific copy number changes in genes, the average CCF for 
that gene was calculated. When timing mutations in genes, the highest CCF amongst the 
non-synonymous mutations was taken.
Neoantigen analyses
Neoantigens in this analysis were defined as all 8–11-mer peptides that arose from an exonic 
nonsynonymous SNV or indel and bound their respective patient’s HLA class I molecules at 
a binding affinity score (IC50) that was ≤ 500 nM and better than or equal to the wild-type 
form of the peptide. Each patient’s 4-digit HLA class I types were inferred using OptiType 
(version 1.3.1, https://github.com/FRED-2/OptiType) run on each patient’s matched normal 
sample58. VCF files for each tumor sample were annotated using Variant Effect Predictor 
(ensembl) with the Downstream and Wildtype plugins. Neoantigens from these VCFs were 
then called using pVACseq (version 4.0.10, https://github.com/griffithlab/pVAC-Seq)40 run 
using netMHCpan (version 2.8, http://www.cbs.dtu.dk/services/NetMHCpan-2.8/)59. For 
each pVACseq run, epitope length was set to 8, 9, 10, or 11, minimum binding affinity fold-
change was set to 1, and downstream sequence length was set to full, with default 
parameters used for all other settings.
Downstream neoantigen analyses were performed using the pVACseq output linked to its 
respective mutation information. Neoantigen-causing mutations were defined as all 
mutations that gave rise to at least one neoantigen. The observed-to-expected neoantigen 
ratio was calculated using a previously developed approach that compares each tumor’s 
observed neoantigen rate to an empirically derived expected rate that assumes no selection 
against neoantigen-causing mutations38: From the gold set samples in the GLASS cohort (n 
= 222), define Ns to be the expected number of nonsynonymous missense SNVs per 
synonymous SNV with trinucleotide context s. Bs is then defined as the expected number of 
neoantigen-generating missense SNVs per nonsynonymous missense SNV with 
trinucleotide context s. For a given sample i, define Yi as the sample’s set of synonymous 
SNVs and s(m) to be a synonymous SNV with trinucleotide context m. The expected 
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number of nonsynonymous missense SNVs, Npred, and neoantigen-causing mutations, Bpred, 
can then be calculated as follows:
Npred, i = ∑
m ∈ Yi
Ns(m)
Bpred, i = ∑
m ∈ Yi
Ns(m)Bs(m)
To obtain sample i’s final neoantigen depletion ratio Ri, the observed number of neoantigen-
causing mutations in the sample, Bobs,i is divided by the sample’s observed number of 
nonsynonymous missense SNVs, Nobs,i, and then this ratio is divided by the ratio of Bpred,i 
and Npred,i. Thus:
Ri =
Bobs, i ∕ Nobs, i
Bpred, i ∕ Npred, i
For analyses examining clonal/subclonal neoantigen ratios, the observed and expected 
numbers were calculated by subsetting a sample’s SNVs by the respective criteria and then 
recalculating the ratio as described above. To mitigate overfitting, all analyses presented here 
utilized samples from patients with at least 3 neoantigen-causing mutations in their primary 
and recurrent tumors.
Immune cell analyses
CIBERSORT relative immune cell fraction data used in downstream neoantigen analyses 
were downloaded from a previous publication37.
Statistical methods
All data analyses were conducted in R 3.4.2, Python 2.7.15, PostgreSQL 10.5, and Julia 0.7. 
All survival analyses including Kaplan-Meier plots and Cox proportional hazards models 
were conducted using the R packages survival and survminer.
Data availability
All deidentified, non-protected access somatic variant profiles and clinical data are 
accessible via Synapse (http://synapse.org/glass). Raw data of the various sequencing 
datasets can be obtained per the overview provided in the Supplement.
Code availability
All custom scripts and pipelines are available on the project’s github page (https://
github.com/TheJacksonLaboratory/GLASS).
Extended Data
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Extended Data Fig. 1 ∣. Sample Selection.
a. Quality control workflow steps identifying all GLASS samples available as a resource and 
the identification of the highest quality set of patient pairs (n = 222) used for the presented 
mutational and copy number analyses. b. Additional available datasets.
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Extended Data Fig. 2 ∣. Mutation burden by time point and subtype.
a. Boxplots and paired lines depicting coverage adjusted mutation frequencies in initial and 
matched recurrent samples across three subtypes. Wilcoxon signed-rank test P-values and 
sample sizes are indicated. b. Bee swarm plot depicting coverage adjusted mutation 
frequencies in fractions by subtype. Dashed line indicates the mean. One-way ANOVA P-
values comparing three subtypes are indicated. c. Scatter plot showing the relationship 
between age at diagnosis and coverage adjusted mutation burdens by subtype and fraction. 
Linear model P-values are indicated and were adjusted by subtype. d. Similar to the analysis 
presented in c, but showing the relationship between time to recurrence and coverage 
adjusted mutation burdens.
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Extended Data Fig. 3 ∣. Mutational signatures by fraction and subtype.
a. Correlation plot showing the Pearson’s chi-squared (X2) residuals for each signature by 
fraction and subtype. A X2 was performed for each subtype and P-values are indicated. 
Positive residuals (blue) indicate a positive correlation, whereas negative residuals (red) 
indicate an anticorrelation. The point size reflects the contribution to X2 estimate. b. The 
same ordered of patients as Fig. 1a along with relevant clinical information is provided 
alongside the fraction-specific mutational signatures. PyClone mutational clusters are also 
presented.
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Extended Data Fig. 4 ∣. Hypermutator clonality.
a. Bar plots represent counts of recurrence-only mutations per hypermutator tumor that were 
known to receive alkylating agent therapy and were successfully run through the PyClone 
algorithm. Colors indicate mutation clonality and color intensity indicates whether the 
mutations resulted in coding changes. b. Kaplan-Meier curve comparing alkylating agent-
treated patients with IDHmut-noncodel hypermutator tumors that were predominantly clonal 
(n = 8), predominantly subclonal (n = 7), versus IDHmut-noncodel non-hypermutators 
known to be treated with alkylating agents and had available PyClone data (n = 17). Log-
rank P-value is shown.
et al. Page 20
Nature. Author manuscript; available in PMC 2020 May 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Extended Data Fig. 5 ∣. Clonal structure evolution over time.
a. The minimum cancer cell fraction of the most persistent (shared between initial and 
recurrence) PyClone cluster. b. Comparison of PyClone clusters ranked by CCF in matched 
initial and recurrent tumors, as Fig. 2b but separated by subtype. c-d. Examples of cluster 
CCF dynamics over time in three separate samples, including (c) two multi-timepoint 
samples (d) and one multi-sector sample. These additional data are available in the GLASS 
resource, but only two time-separated samples were used throughput the manuscript to 
ensure clarity.
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Extended Data Fig. 6 ∣. Variant allele fraction distribution
(a) Non-hypermutator variant allele fraction distributions for copy neutral variants in coding 
regions (n = 181 patients). Variants are separated by subtype, fraction, and also whether the 
variant was non-synonymous or synonymous mutation in a coding region. R2 goodness-of-
fit measure and associated P-values are shown for both mutation types. Note that this data 
considers only the coding portion of genome while Fig. 2d presents both coding and non-
coding. (b) The cumulative distribution of the subclonal mutations in copy-neutral regions 
for hypermutators (n = 31 patients). For each variant fraction and subtype, the R2 goodness-
of-fit measure and P-values are shown.
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Extended Data Fig. 7 ∣. Driver gene nomination.
a. Local (gene-wise) dNdScv estimates by subtype (rows) and fraction (columns). Genes are 
sorted by Q-value and P-value. The Q-value is shown in color, whereas the P-value is 
indicated in light gray. The Q-value threshold of 0.05 is indicated by a horizontal red line. b. 
GISTIC significant amplification (red) and deletion (blue) plots in initial (left) and recurrent 
tumors (right). Chromosomal locations are ordered on the y-axis, Q-values are shown on the 
x-axis, and selected drivers are indicated by their chromosomal location on the right.
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Extended Data Fig. 8 ∣. Driver acquisition over time
a. Tabulated numbers of SNV (top) and CNV (bottom) driver events that were shared, 
initial-only, or recurrence-only. P-values were obtained using a two-sided Fisher test 
comparing the initial-only fraction to the recurrence-only fraction testing for acquisition. b. 
One-sided Fisher test comparing the initial-only fraction to the recurrence-only fraction 
amongst previously implicated glioma drivers testing for driver acquisition. P-values were 
adjusted for multiple testing using the FDR (x-axis). Hypermutators (red) and non-
hypermutators (black) were separately analyzed.
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Extended Data Fig. 9 ∣. Intra-tumor CCF comparison.
Ladder plots comparing the CCF of co-occurring drivers in single tumor samples. The color 
of the lines and points indicates whether the sample shown is an initial (brown) or recurrent 
(green) tumor. Two-sided Wilcoxon rank-sum test P-values are shown for all initial samples, 
all recurrent samples, as well as all samples (black).
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Extended Data Fig. 10 ∣. Between time point intra-patient CCF comparison.
a. Driver-gene CCF comparison between initial and matched recurrences. Lines are colored 
by variant classification. Two-sided Wilcoxon rank-sum test P-values are shown. b. TP53 
CCF by subtype, otherwise as in (a). c. IDH1 CCF by subtype, otherwise as in (a). d. Ladder 
plot visualizing CCF change across all SNVs between initial and recurrent tumors, separated 
by subtype. Wilcoxon rank-sum test was used to test for differences between time points. e. 
Initial and recurrent mutations in each patient were compared using a Wilcoxon rank-sum 
test. Bar plot with counts of patients in each subtype are shown. Patients lacking significant 
change are shown in yellow, those with a significant increase or decrease are shown in dark 
and light blue, respectively.
et al. Page 26
Nature. Author manuscript; available in PMC 2020 May 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Extended Data Fig. 11 ∣. Aneuploidy calculation
a. Heatmap displaying the chromosomal arm-level events (x-axis) with patients represented 
in each row. Patients are placed in the same order for both the initial (left) and recurrence 
(right). White space was inserted as a break between the three subtypes. b. Distribution of 
total aneuploidy difference. Acquired aneuploidy determination (upper-quartile) indicated 
with a red line. c. Comparison of aneuploidy score between initial and recurrent tumors 
separated by subtype d. As (c), comparing aneuploidy value.
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Extended Data Fig. 12 ∣. Neoantigen evolution and cellular analysis
a. Bar plots representing the number of shared mutations that give rise to neoantigens (top 
row, “immunogenic”) and those that do not give rise to neoantigens (bottom row, “non-
immunogenic”) stratified by longitudinal clonality (“(clonality in initial)-(clonality in 
recurrence)”) and further separated by subtype. Percentage of longitudinal clonality per 
subtype and mutation immunogenicity are presented above the respective bars. b. Left: 
Ladder plot depicting the difference in observed-to-expected neoantigen ratio between the 
initial and recurrent tumors of patients with hypermutated tumors at recurrence. Each set of 
points connected by a line represents one tumor (n = 70). Right: Boxplot depicting the 
distribution of observed to expected neoantigen ratios in recurrent tumors stratified by 
hypermutator status (n = 35 and 183 for hypermutators and non-hypermutators, 
respectively). Each box spans quartiles, with the lines representing the median ratio for each 
group. Whiskers represent absolute range, excluding outliers. P-values for panel b were 
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calculated using a paired and unpaired two-sided t-test, respectively. c. Stacked bar plots 
depicting the average relative fraction of 11 CIBERSORT cell types in the neoantigen 
depleted (< 1) and non-depleted (> 1) initial and recurrent tumor subgroups. Asterisks to the 
right of each plot indicate a significant difference (P < 0.05, Wilcoxon rank-sum test) 
between the depleted and non-depleted groups for the noted cell type at that time.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Authors 
The Glioma Longitudinal Analysis (GLASS) Consortium, Floris P. Barthel1,2,54, 
Kevin C. Johnson1,54, Frederick S. Varn1, Anzhela D. Moskalik1, Georgette Tanner3, 
Emre Kocakavuk1,4, Kevin J. Anderson1, Olajide Abiola1, Kenneth Aldape5, Kristin 
D. Alfaro6, Donat Alpar7,8, Samirkumar B. Amin1, David M. Ashley9, Pratiti 
Bandopadhayay10,11, Jill S. Barnholtz-Sloan12, Rameen Beroukhim10,11, Christoph 
Bock7,13, Priscilla K. Brastianos14, Daniel J. Brat15, Andrew R. Brodbelt16, 
Alexander F. Bruns3, Ketan R. Bulsara17, Aruna Chakrabarty18, Arnab 
Chakravarti19, Jeffrey H. Chuang1,20, Elizabeth B. Claus21,22, Elizabeth J. 
Cochran23, Jennifer Connelly23, Joseph F. Costello24, Gaetano Finocchiaro25, 
Michael N. Fletcher26, Pim J. French27, Hui K. Gan28,29,30, Mark R. Gilbert31, Peter 
V. Gould32, Matthew R. Grimmer24, Antonio Iavarone33, Azzam Ismail18, Michael D. 
Jenkinson16, Mustafa Khasraw34, Hoon Kim1, Mathilde C.M. Kouwenhoven2, Peter 
S. LaViolette23, Meihong Li1, Peter Lichter26, Keith L. Ligon10,11, Allison K. 
Lowman23, Tathiane M. Malta35, Tali Mazor24, Kerrie L. McDonald36, Annette M. 
Molinaro24, Do-Hyun Nam37, Naema Nayyar14, Ho Keung Ng38, Chew Yee Ngan1, 
Simone, P. Niclou39, Johanna M. Niers2, Houtan Noushmehr35, Javad Noorbakhsh1, 
D. Ryan Ormond40, Chul-Kee Park41, Laila M. Poisson35, Raul Rabadan33, 
Bernhard Radlwimmer26, Ganesh Rao6, Guido Reifenberger42, Jason K. Sa43, 
Michael Schuster7, Brian L. Shaw14, Susan C. Short3, Peter A. Sillevis Smitt27, 
Andrew E. Sloan44, Marion Smits27, Hiromichi Suzuki45, Ghazaleh Tabatabai46, 
Erwin G. Van Meir47, Colin Watts48, Michael Weller49, Pieter Wesseling2,50, Bart A. 
Westerman2, Georg Widhalm51, Adelheid Woehrer52, W.K. Alfred Yung6, Gelareh 
Zadeh53, GLASS Consortium, Jason T. Huse6, John F. de Groot6, Lucy F. Stead3, 
Roel G.W. Verhaak1,¥
Affiliations
1The Jackson Laboratory for Genomic Medicine, Farmington, CT, 06032, USA. 
2Amsterdam UMC, Vrije Universiteit Amsterdam, Departments of Neurology, 
Neurosurgery, Pathology, Brain Tumor Center Amsterdam, de Boelelaan 1117, 
Amsterdam, Netherlands 3Leeds Institute of Medical Research at St James’s, 
University of Leeds, LS9 7TF, UK. 4DKFZ Division of Translational Neurooncology at 
the West German Cancer Center, German Cancer Consortium Partner Site & 
Department of Neurosurgery, University Hospital Essen, 45147 Essen, Germany 
5National Cancer Institute, Bethesda, MD 20892, USA 6Departments of Neuro-
et al. Page 29
Nature. Author manuscript; available in PMC 2020 May 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Oncology, Neurosurgery, Pathology, Translational Molecular Pathology, The 
University of Texas MD Anderson Cancer Center, Houston, Texas 77031, USA 
7CeMM Research Center for Molecular Medicine of the Austrian Academy of 
Sciences, 1090 Vienna, Austria 81st Department of Pathology and Experimental 
Cancer Research, Semmelweis University, 1085 Budapest, Hungary 9Preston 
Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, 
North Carolina 27710, USA 10Dana-Farber Cancer Institute, 450 Brookline Ave, 
Boston, MA 02215, USA 11Broad Institute, 415 Main Street, Cambridge, MA 02142, 
USA 12Department of Population and Quantitative Health Sciences and Case 
Comprehensive Cancer Center, Case Western Reserve University School of 
Medicine, 2103 Cornell Rd, WRB 2-526, Cleveland, Ohio 44106, USA 13Department 
of Laboratory Medicine, Medical University of Vienna, Vienna, Austria 14Division of 
Neuro-Oncology, Massachusetts General Hospital, Boston, MA 02114, USA 
15Department of Pathology, Northwestern University Feinberg School of Medicine, 
Chicago IL, 60611, USA 16University of Liverpool & Walton Centre NHS Trust, 
Liverpool, L9 7LJ, UK 17Division of Neurosurgery, The University of Connecticut 
Health Center, Farmington, CT, USA 18Leeds Teaching Hospital NHS Trust, St 
James’s University Hospital, Leeds, LS9 7TF, UK 19Department of Radiation 
Oncology, Arthur G. James Hospital/Ohio State Comprehensive Cancer Center, 
Columbus, OH, 43210, USA 20UConn Health, Department of Genetics and Genome 
Sciences, Farmington, CT, 06030, USA 21Yale University School of Public Health, 
New Haven, CT, 06511, USA 22Department of Neurosurgery, Brigham and Women’s 
Hospital, Boston, MA, USA 23Departments of Neurology, Pathology, Radiology and 
Biomedical Engineering, Medical College of Wisconsin, Milwaukee, WI USA 
24Department of Neurosurgery, University of California San Francisco, CA 94143, 
USA 25Fondazione IRCCS Istituto Neurologico Besta, Milano, Italy 26Division of 
Molecular Genetics, Heidelberg Center for Personalized Oncology, German Cancer 
Research Consortium, German Cancer Research Center (DKFZ), Heidelberg, 
Germany 27Departments of Neurology, Radiology and Nuclear Medicine, Erasmus 
MC - University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, the 
Netherlands 28Olivia Newton-John Cancer Research Institute, Austin Health, 
Melbourne, Australia 29La Trobe University School of Cancer Medicine, Heidelberg, 
Victoria, Australia 30Department of Medicine, University of Melbourne, Heidelberg, 
Victoria, AustraliaNeuro-oncology Branch, National Institutes of Health, Bethesda, 
Maryland, 20892, USA 31Neuro-oncology Branch, National Institutes of Health, 
Bethesda, Maryland, 20892, USA 32Anatomic Pathology Service, Hôpital de 
l’Enfant-Jésus, CHU de Québec-Université Laval, Québec QC G1J 1Z4, Canada 
33Departments of Neurology, Pathology, Cell Biology, Systems Biology and 
Biomedical Informatics, Institute for Cancer Genetics, Columbia University Medical 
Center, New York, New York 10032, USA 34Cooperative Trials Group for Neuro-
Oncology (COGNO) NHMRC Clinical Trials Centre, The University of Sydney, New 
South Wales, Australia 35Departments of Neurosurgery, Public Health Sciences, 
Henry Ford Health System, Henry Ford Cancer Institute, Detroit, MI 48202, USA 
36Cure Brain Cancer Biomarkers and Translational Research Group, Prince of 
et al. Page 30
Nature. Author manuscript; available in PMC 2020 May 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Wales Clinical School, UNSW Sydney, Australia 37Department of Neurosurgery, 
Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, 
Korea 38Department of Anatomical and Cellular Pathology, The Chinese University 
of Hong Kong, 1/F, Prince of Wales Hospital, Shatin, Hong Kong 39Department of 
Oncology, Luxembourg Institute of Health, Luxembourg 40Department of 
Neurosurgery, University of Colorado School of Medicine, Aurora, Colorado, 80045, 
USA 41Department of Neurosurgery, Seoul National University College of Medicine, 
Seoul National University Hospital, Seoul, Korea 42Institute of Neuropathology, 
Heinrich Heine University Düsseldorf, Düsseldorf, Germany 43Institute for Refractory 
Cancer Research, Samsung Medical Center, Seoul, Korea 44Department of 
Neurosurgery, University Hospitals-Case Medical Center, Seidman Cancer Center, 
and the Case Comprehensive Cancer Center, Cleveland, Ohio 44106, USA 45The 
Hospital for Sick Children, Toronto, ON, M5G1X8, Canada 46Interdiscplinary 
Division of Neuro-Oncology, Hertie Institute for Clinical Brain Research, DKTK 
Partner Site Tübingen, Eberhard Karls University Tübingen, Germany 47Department 
of Neurosurgery, School of Medicine and Winship Cancer Institute of Emory U 
University; 1365C Clifton Rd. NE, Atlanta, GA30084, USA 48Institute of Cancer 
Genome Sciences, Department of Neurosurgery, University of Birmingham, UK 
49Department of Neurology, University Hospital Zurich, Zurich, Switzerland 
50Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands 
51Department of Neurosurgery, Medical University of Vienna, 1090 Vienna, Austria 
52Institute of Neurology, Medical University of Vienna, 1090 Vienna, Austria 
53Division of Neurosurgery, Department of Surgery, University Health Network, 
Toronto, C Canada. 54These authors contributed equally.
ACKNOWLEDGEMENTS
This work is dedicated to the memory of Simone Bischoff-Lardenoije and is made possible by the patients and their 
families whom generously contributed to this study. This work is supported by the National Brain Tumor Society, 
Oligo Research Fund; Cancer Center Support grants P30CA16672 and P30CA034196; Cancer Prevention & 
Research Institute of Texas (CPRIT) grant number R140606; Agilent Technologies (R.G.W.V.); the National 
Institutes of Health- National Cancer institute for the following grants: NCI CA170278 (L.M.P., M.M.T., N.H.), 
NCI R01CA222146 (L.M.P, N.H.), NCI R01CA230031 (J.H.C., J.N.), NCI R01CA188288 (J.S.B., R.B., P.B., 
K.L.L., A.C., A.E.S.), R01CA179044 (Antonio Iavarone), U54CA193313 (Antonio Iavarone). The National Brain 
Tumor Society (W.K.A.Y.; J.D.G). Brain Tumour Northwest tissue bank (including the Walton research tissue bank) 
is supported by the Sidney Driscol Neuroscience Foundation and part of the Walton Centre and Lancashire 
Teaching Hospitals NHS Foundation Trusts (A.B., M.D.J.). This work was supported by a generous gift from the 
Dabbiere family (J.F.C.). Support is also provided by a Leeds Charitable Foundation grant (9R11/14‐11 to LFS), 
University of Leeds Academic Fellowship (11001061) (L.F.S.) and Studentship (11061191) (G.T.) as well as Leeds 
Teaching Hospitals NHS Trust (Aruna Chakravarti, Azzam Ismail). The Leeds Multidisciplinary Research Tissue 
Bank staff was funded by the PPR Foundation and The University of Leeds (S.C.S.). Funds were received from The 
Brain Tumour Charity (C.W., Grants 10/136 & GN-000580, B.A.W., 200450). G.T. is funded by EKFS 
2015_Kolleg_14. R01CA218144 (P.S.L, E.J.C, J.C. A.K.L.) and Strain for the Brain, Milwaukee, WI (P.S.L, E.J.C, 
J.C. A.K.L.). E.K is recipient of an MD-Fellowship by the Boehringer Ingelheim Fonds and is supported by the 
German National Academic Foundation. The Leeds Multidisciplinary Research Tissue Bank staff was funded by 
the PPR Foundation and part of the University of Leeds (S.C.S.). GLASS-Austria was funded by the Austrian 
Science Fund project KLI394 (A.W.). GLASS-Germany was funded by the German Ministry of Education and 
Research (BMBF) 031A425 (G.R., P.L.) and German Cancer Aid (DKH) 70–3163-Wi 3 (M.W.). GLASS-NL 
receives support from KWF/Dutch Cancer Society project11026 (MCMK, PW, RGWV, PJF, JMN, MS, BAW). We 
thank the University of Colorado Denver Central Nervous System Biorepository (D.R.O.) for providing tissue 
samples. Sponsoring was also received from the National Institute of Neurological Disorders and Stroke (NINDS 
R01NS094615, R.G.), National Health and Medical Research Council project grant (A.M.D.). F.S.V. is supported 
et al. Page 31
Nature. Author manuscript; available in PMC 2020 May 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
by a postdoctoral fellowship from The Jane Coffin Childs Memorial Fund for Medical Research. F.P.B. is supported 
by the JAX Scholar program and the National Cancer Institute (K99 CA226387); K.C.J. is the recipient of an 
American Cancer Society Fellowship (130984-PF-17–141-01-DMC). We thank the Jackson Laboratory Clinical 
and Translation Support team for coordinating all data transfer agreements. We thank Matt Wimsatt for assistance 
in graphic design.
References
1. Barthel FP, Wesseling P & Verhaak RGW Reconstructing the molecular life history of gliomas. Acta 
Neuropathol 135, 649–670, doi:10.1007/s00401-018-1842-y (2018). [PubMed: 29616301] 
2. Sturm D et al. Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev 
Cancer 14, 92–107, doi:10.1038/nrc3655 (2014). [PubMed: 24457416] 
3. Bettegowda C et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 
333, 1453–1455, doi:10.1126/science.1210557 (2011). [PubMed: 21817013] 
4. Zheng S et al. A survey of intragenic breakpoints in glioblastoma identifies a distinct subset 
associated with poor survival. Genes Dev 27, 1462–1472, doi:10.1101/gad.213686.113 (2013). 
[PubMed: 23796897] 
5. Cancer Genome Atlas Research, N. Comprehensive genomic characterization defines human 
glioblastoma genes and core pathways. Nature 455, 1061–1068, doi:10.1038/nature07385 (2008). 
[PubMed: 18772890] 
6. Ceccarelli M et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of 
Progression in Diffuse Glioma. Cell 164, 550–563, doi:10.1016/j.cell.2015.12.028 (2016). 
[PubMed: 26824661] 
7. TCGA_Network et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade 
Gliomas. N Engl J Med 372, 2481–2498, doi:10.1056/NEJMoa1402121 (2015). [PubMed: 
26061751] 
8. Verhaak RG et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma 
characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98–110, doi:
10.1016/j.ccr.2009.12.020 (2010). [PubMed: 20129251] 
9. Yan H et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 360, 765–773, doi:10.1056/
NEJMoa0808710 (2009). [PubMed: 19228619] 
10. Louis DN et al. International Society Of Neuropathology--Haarlem consensus guidelines for 
nervous system tumor classification and grading. Brain Pathol 24, 429–435, doi:10.1111/bpa.
12171 (2014). [PubMed: 24990071] 
11. Louis DN et al. The 2016 World Health Organization Classification of Tumors of the Central 
Nervous System: a summary. Acta Neuropathol 131, 803–820, doi:10.1007/s00401-016-1545-1 
(2016). [PubMed: 27157931] 
12. Venteicher AS et al. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas 
by single-cell RNA-seq. Science 355, doi:10.1126/science.aai8478 (2017).
13. Patel AP et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. 
Science 344, 1396–1401, doi:10.1126/science.1254257 (2014). [PubMed: 24925914] 
14. Snuderl M et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. 
Cancer Cell 20, 810–817, doi:10.1016/j.ccr.2011.11.005 (2011). [PubMed: 22137795] 
15. Sottoriva A et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary 
dynamics. Proc Natl Acad Sci U S A 110, 4009–4014, doi:10.1073/pnas.1219747110 (2013). 
[PubMed: 23412337] 
16. Williams MJ et al. Quantification of subclonal selection in cancer from bulk sequencing data. Nat 
Genet 50, 895–903, doi:10.1038/s41588-018-0128-6 (2018). [PubMed: 29808029] 
17. Nejo T et al. Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible 
Immune Evasion Mechanism in Glioma. Cancer Immunol Res, doi:
10.1158/2326-6066.CIR-18-0599 (2019).
18. Consortium G Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the 
Glioma Longitudinal Analysis Consortium. Neuro Oncol 20, 873–884, doi:10.1093/neuonc/
noy020 (2018). [PubMed: 29432615] 
et al. Page 32
Nature. Author manuscript; available in PMC 2020 May 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
19. Hu H et al. Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain 
Tumor. Cell 175, 1665–1678 e1618, doi:10.1016/j.cell.2018.09.038 (2018). [PubMed: 30343896] 
20. Alexandrov LB et al. Signatures of mutational processes in human cancer. Nature 500, 415–421, 
doi:10.1038/nature12477 (2013). [PubMed: 23945592] 
21. Wang J et al. Clonal evolution of glioblastoma under therapy. Nat Genet 48, 768–776, doi:
10.1038/ng.3590 (2016). [PubMed: 27270107] 
22. Kim H et al. Whole-genome and multisector exome sequencing of primary and post-treatment 
glioblastoma reveals patterns of tumor evolution. Genome Res 25, 316–327, doi:10.1101/gr.
180612.114 (2015). [PubMed: 25650244] 
23. Johnson BE et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent 
glioma. Science 343, 189–193, doi:10.1126/science.1239947 (2014). [PubMed: 24336570] 
24. Hunter C et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human 
malignant gliomas after alkylator chemotherapy. Cancer Res 66, 3987–3991, doi:
10.1158/0008-5472.CAN-06-0127 (2006). [PubMed: 16618716] 
25. Jolly C & Van Loo P Timing somatic events in the evolution of cancer. Genome Biol 19, 95, doi:
10.1186/s13059-018-1476-3 (2018). [PubMed: 30041675] 
26. Turajlic S, Sottoriva A, Graham T & Swanton C Resolving genetic heterogeneity in cancer. Nat 
Rev Genet, doi:10.1038/s41576-019-0114-6 (2019).
27. Choi S et al. Temozolomide-associated hypermutation in gliomas. Neuro Oncol 20, 1300–1309, 
doi:10.1093/neuonc/noy016 (2018). [PubMed: 29452419] 
28. Baumert BG et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma 
(EORTC 22033–26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 17, 
1521–1532, doi:10.1016/S1470-2045(16)30313–8 (2016). [PubMed: 27686946] 
29. Buckner JC et al. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N 
Engl J Med 374, 1344–1355, doi:10.1056/NEJMoa1500925 (2016). [PubMed: 27050206] 
30. Yap TA, Gerlinger M, Futreal PA, Pusztai L & Swanton C Intratumor heterogeneity: seeing the 
wood for the trees. Sci Transl Med 4, 127ps110, doi:10.1126/scitranslmed.3003854 (2012).
31. Williams MJ, Werner B, Barnes CP, Graham TA & Sottoriva A Identification of neutral tumor 
evolution across cancer types. Nat Genet 48, 238–244, doi:10.1038/ng.3489 (2016). [PubMed: 
26780609] 
32. Korber V et al. Evolutionary Trajectories of IDH(WT) Glioblastomas Reveal a Common Path of 
Early Tumorigenesis Instigated Years ahead of Initial Diagnosis. Cancer Cell 35, 692–704 e612, 
doi:10.1016/j.ccell.2019.02.007 (2019). [PubMed: 30905762] 
33. deCarvalho AC et al. Discordant inheritance of chromosomal and extrachromosomal DNA 
elements contributes to dynamic disease evolution in glioblastoma. Nat Genet 50, 708–717, doi:
10.1038/s41588-018-0105-0 (2018). [PubMed: 29686388] 
34. Giam M & Rancati G Aneuploidy and chromosomal instability in cancer: a jackpot to chaos. Cell 
Div 10, 3, doi:10.1186/s13008-015-0009-7 (2015). [PubMed: 26015801] 
35. Marty R, Thompson WK, Salem RM, Zanetti M & Carter H Evolutionary Pressure against MHC 
Class II Binding Cancer Mutations. Cell 175, 416–428 e413, doi:10.1016/j.cell.2018.08.048 
(2018). [PubMed: 30245014] 
36. McGranahan N et al. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. 
Cell 171, 1259–1271 e1211, doi:10.1016/j.cell.2017.10.001 (2017). [PubMed: 29107330] 
37. Wang Q et al. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with 
Immunological Changes in the Microenvironment. Cancer Cell 32, 42–56 e46, doi:10.1016/j.ccell.
2017.06.003 (2017). [PubMed: 28697342] 
38. Rooney MS, Shukla SA, Wu CJ, Getz G & Hacohen N Molecular and genetic properties of tumors 
associated with local immune cytolytic activity. Cell 160, 48–61, doi:10.1016/j.cell.2014.12.033 
(2015). [PubMed: 25594174] 
39. Dunn GP, Bruce AT, Ikeda H, Old LJ & Schreiber RD Cancer immunoediting: from 
immunosurveillance to tumor escape. Nat Immunol 3, 991–998, doi:10.1038/ni1102-991 (2002). 
[PubMed: 12407406] 
40. Hundal J et al. pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens. 
Genome Med 8, 11, doi:10.1186/s13073-016-0264-5 (2016). [PubMed: 26825632] 
et al. Page 33
Nature. Author manuscript; available in PMC 2020 May 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
41. Newman AM et al. Robust enumeration of cell subsets from tissue expression profiles. Nat 
Methods 12, 453–457, doi:10.1038/nmeth.3337 (2015). [PubMed: 25822800] 
42. Rosenthal R et al. Neoantigen-directed immune escape in lung cancer evolution. Nature 567, 479–
485, doi:10.1038/s41586-019-1032-7 (2019). [PubMed: 30894752] 
43. Raub TJ et al. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the 
Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an 
Intracranial Glioblastoma Xenograft. Drug Metab Dispos 43, 1360–1371, doi:10.1124/dmd.
114.062745 (2015). [PubMed: 26149830] 
44. van den Bent M et al. Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients 
with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. 
Cancer Chemother Pharmacol 80, 1209–1217, doi:10.1007/s00280-017-3451-1 (2017). [PubMed: 
29075855] 
45. Keskin DB et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib 
glioblastoma trial. Nature 565, 234–239, doi:10.1038/s41586-018-0792-9 (2019). [PubMed: 
30568305] 
46. Schumacher T et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512, 
324–327, doi:10.1038/nature13387 (2014). [PubMed: 25043048] 
47. Koster J & Rahmann S Snakemake-a scalable bioinformatics workflow engine. Bioinformatics 34, 
3600, doi:10.1093/bioinformatics/bty350 (2018). [PubMed: 29788404] 
48. Van der Auwera GA et al. From FastQ data to high confidence variant calls: the Genome Analysis 
Toolkit best practices pipeline. Curr Protoc Bioinformatics 43, 11 10 11–33, doi:
10.1002/0471250953.bi1110s43 (2013). [PubMed: 25431634] 
49. Ewels P, Magnusson M, Lundin S & Kaller M MultiQC: summarize analysis results for multiple 
tools and samples in a single report. Bioinformatics 32, 3047–3048, doi:10.1093/bioinformatics/
btw354 (2016). [PubMed: 27312411] 
50. Li H et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079, 
doi:10.1093/bioinformatics/btp352 (2009). [PubMed: 19505943] 
51. Mermel CH et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal 
somatic copy-number alteration in human cancers. Genome Biol 12, R41, doi:10.1186/
gb-2011-12-4-r41 (2011). [PubMed: 21527027] 
52. Beroukhim R et al. Assessing the significance of chromosomal aberrations in cancer: methodology 
and application to glioma. Proc Natl Acad Sci U S A 104, 20007–20012, doi:10.1073/pnas.
0710052104 (2007). [PubMed: 18077431] 
53. Martincorena I et al. Universal Patterns of Selection in Cancer and Somatic Tissues. Cell 171, 
1029–1041 e1021, doi:10.1016/j.cell.2017.09.042 (2017). [PubMed: 29056346] 
54. Taylor AM et al. Genomic and Functional Approaches to Understanding Cancer Aneuploidy. 
Cancer Cell 33, 676–689 e673, doi:10.1016/j.ccell.2018.03.007 (2018). [PubMed: 29622463] 
55. Roth A et al. PyClone: statistical inference of clonal population structure in cancer. Nat Methods 
11, 396–398, doi:10.1038/nmeth.2883 (2014). [PubMed: 24633410] 
56. Turajlic S et al. Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx 
Renal. Cell 173, 581–594 e512, doi:10.1016/j.cell.2018.03.057 (2018). [PubMed: 29656895] 
57. Ha G et al. TITAN: inference of copy number architectures in clonal cell populations from tumor 
whole-genome sequence data. Genome Res 24, 1881–1893, doi:10.1101/gr.180281.114 (2014). 
[PubMed: 25060187] 
58. Szolek A et al. OptiType: precision HLA typing from next-generation sequencing data. 
Bioinformatics 30, 3310–3316, doi:10.1093/bioinformatics/btu548 (2014). [PubMed: 25143287] 
59. Hoof I et al. NetMHCpan, a method for MHC class I binding prediction beyond humans. 
Immunogenetics 61, 1–13, doi:10.1007/s00251-008-0341-z (2009). [PubMed: 19002680] 
et al. Page 34
Nature. Author manuscript; available in PMC 2020 May 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 1 ∣. Temporal changes in glioma mutational burden and processes.
a. Each column represents a single patient (n = 222) at two separate timepoints grouped by 
glioma subtype and ordered left-to-right by decreasing mutation frequency at recurrence. 
Top, mutation frequency differences between initial and recurrent tumors. Blue dotted line 
indicates increased mutation frequency while a red dotted line indicates decreased 
mutational frequency. Stacked bar plot reflects the proportion of total mutations shared 
(mustard), private to initial (magenta), or private to recurrence (blue). Clinical information 
including hypermutation status, therapy, and grade changes. b. Stacked bar plot (n=219) 
indicating the dominant mutational signature among initial, recurrent and shared mutation 
fractions stratified by glioma subtype. c. The proportion of glioma recurrences with 
alkylating agent-related hypermutation, grouped by glioma subtype. Fisher’s exact test was 
used to compare proportions between subtypes. d. Kaplan-Meier curve depicting overall 
survival in hypermutant (red) versus non-hypermutant (blue) alkylating agent treated 
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patients amongst IDHwt (left, n = 99) and IDHmut-noncodel (right, n = 32) tumors. Log-
rank test P-values are shown.
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Fig. 2 ∣. Quantifying selective pressures during glioma evolution.
a. Schematic depiction of cancer cell fraction (CCF) values during tumor evolution 
indicating clonality and associated relative timing. b. Comparison of PyClone clusters 
ranked by CCF in matched initial and recurrent tumors. c. Left: dN/dS ratio for all variants 
(i.e. global) in initial and recurrent tumors for each subtype. Hypermutators were not 
included (n = 187). Dots represent the global dN/dS ratio with associated Wald confidence 
intervals. Right: global dN/dS ratios for variant fractions per subtype. d. Cumulative 
distribution of subclonal mutations by their inverse variant allele frequency. Mutations were 
separated by timepoint, variant fraction, and glioma subtype. Deviation from a linear 
relationship, significant Kolmogorov-Smirnov P-values and R2 below 0.98 indicate 
selection. e. Sankey plot indicating the breakdown of SubClonalSelection evolutionary 
modes by subtype and therapy (n = 104). The sizes of the bands reflect sample sizes and 
band colors highlight the glioma subtype. Gray coloring reflects instances when treatment 
information was not available. f. Kaplan-Meier curve showing survival differences between 
et al. Page 37
Nature. Author manuscript; available in PMC 2020 May 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
IDHwt recurrent tumors demonstrating selection (n = 39) compared with neutrally evolving 
tumors (n = 44). Log-rank P-value is indicated.
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Fig. 3 ∣. Patterns of glioma driver frequencies over time.
a. Driver dynamics for SNVs nominated by the dNdScv and CNVs nominated by GISTIC (n 
= 222). Each column represents a single patient at two separate time points stratified by 
subtype and ordered left-to-right by the number of driver alterations. The degree of 
aneuploidy difference (recurrence – initial) offers a summary metric for increases (> 0) or 
decreases (< 0) in aneuploidy at recurrence. Variants are marked and different shapes 
indicate whether a variant was shared or private. The variant type is depicted by its color. 
Stacked bar plots accompanying each gene/arm provide cohort-level proportions for whether 
the alteration was shared, lost, or acquired. b. Aneuploidy comparison in matching initial 
and recurrent IDHmut-noncodel tumors. c. Within-sample CCF comparison of CDKN2A 
homozygous deletion (homdel) to genome-wide CCF as a proxy for aneuploidy. A relative 
higher CCF indicates temporal precedence. Wilcoxon signed-rank test P-value is indicated. 
d. Kaplan-Meier curve comparing survival in IDHmut-noncodel tumors with an alteration in 
the cell cycle, acquired aneuploidy, or both (shades of red) versus unaltered IDHmut-
noncodel tumors (blue). Log-rank P-value is shown.
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Fig. 4 ∣. Neoantigen selection during tumor progression.
a. Mean proportion of coding mutations giving rise to neoantigens (neoantigens/
nonsynonymous) stratified by glioma subtype and timepoint (n = 222). Error bars represent 
standard deviation. b. Boxplot depicting the distribution of observed to expected neoantigen 
ratios in the GLASS cohort stratified by glioma subtype. P-value was calculated using the 
Wilcoxon rank-sum test. Each box spans quartiles, with the lines representing the median 
ratio for each group. Whiskers represent absolute range, excluding outliers. c. Scatterplot 
depicting the association between the observed-to-expected neoantigen ratio in a patient’s 
initial versus recurrent tumor. Each point represents a single patient. R represents Pearson 
correlation coefficient. Panels b and c only include samples with at least 3 neoantigens in the 
initial and recurrent tumors (n = 131, 63, and 24 for IDHwt, IDHmut-noncodel, and 
IDHmut-codel, respectively). d. Ladder plot depicting the difference in observed-to-
expected neoantigen ratio between a tumor’s clonal and subclonal neoantigens. Each set of 
points connected by a line represents one tumor. Tumors are stratified by whether they were 
a patient’s initial or recurrent tumor. Lines are colored by each patient’s glioma subtype. 
Panel d only includes samples with at least 3 clonal neoantigens and at least 3 subclonal 
neoantigens in both the initial and recurrent tumors (n = 35, 20 and 9 for IDHwt, IDHmut-
noncodel, and IDHmut-codel, respectively). P-value was calculated using a paired two-sided 
t-test. Colors in each panel represent the glioma subtype and are denoted at the bottom of the 
figure.
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